was cleaved to tGLP-1 in vitro by purified recombinant PC3. Taken together, these results indicate that PC3 has the same specificity as the convertase that is responsible for the processing of proglucagon to tGLP-1, glicentin and oxyntomodulin in the intestinal L cell, and it is concluded that this enzyme is thus able to act alone in this processing pathway.
Proglucagon is processed differentially in pancreatic
Finally, GLP-1-(1-37) was cleaved to tGLP-1 in vitro by purified recombinant PC3. Taken together, these results indicate that PC3 has the same specificity as the convertase that is responsible for the processing of proglucagon to tGLP-1, glicentin and oxyntomodulin in the intestinal L cell, and it is concluded that this enzyme is thus able to act alone in this processing pathway.
A large number of proteins and peptides are synthesized as larger precursors that are proteolytically processed during their intracellular transport to produce the biologically active molecules. The hallmark of this intracellular maturation, which takes place relatively late in the secretory pathway, is its high specificity for sites containing basic residues. The specific endoproteases that carry out these cleavages belong to the recently identified family of subtilisin-like pro-protein convertases or SPC (1) (2) (3) . Two members of this family, PC2 (SPC2) and PC3 (SPC3, also known as PC1), are expressed in neural and endocrine tissues and are active in the regulated secretory pathway of these cells. PC2 and PC3 have been implicated in the processing of a growing number of prohormones and proneuropeptides (4 -18) . Their specificities toward various cleavage sites appear to be distinct, although overlapping, and variations in their levels of expression may be responsible for the differential processing of a given precursor as suggested for the processing of pro-opiomelanocortin (19 -21) , and proglucagon (22, 23) .
Proglucagon is alternatively processed to glucagon or to tGLP-1, 1 two hormones having opposing biological activities, in the ␣-cells of the Islet of Langerhans in the pancreas and in the endocrine L cells of the intestinal mucosa, respectively (24 -26) . In the pancreas, the processing leads to the production of GRPP, glucagon, IP-1, and MPGF as major endproducts (27) (28) (29) , whereas glicentin, GRPP, oxyntomodulin, tGLP-1, IP-2, and GLP-2 have been found in intestinal extracts (29 -32) (Fig.  1) . The first indication that this differential processing may result from the expression of different convertases in ␣-and L cells came from the observation that pancreatic ␣-cells express high levels of PC2 but no detectable PC3 (8, (33) (34) (35) (36) , whereas intestinal L cells contain immunoreactive PC3 but no PC2 (37) . The pancreatic pathway of proglucagon processing has been determined in ␣TC1-6 cells, a transformed cell line processing proglucagon in a manner that faithfully reflects the parental pancreatic ␣-cell from which it has been derived (8) . In these cells, proglucagon is initially cleaved at the site Lys 70 -Arg 71 between glicentin and MPGF. Glicentin is later fully processed to glucagon, whereas MPGF accumulates and is only partially converted to GLP-1-(1-36amide), a 4 kDa N-terminally extended form of GLP-1 different from the tGLP-1 found in the intestine (see Fig. 1 ). All these cleavages were shown to be catalyzed by PC2 (8, 23, 38) . This was recently confirmed by the disruption of the gene of this convertase, which led to the absence of glucagon and the secretion of inactive proglucagon from the ␣-cells of SPC2 -/-mice (39) . With the same convertase being responsible for both the early and late cleavages, it has been proposed that the structure of the precursor could be responsible for the temporal order of the cleavages (1). Proglucagon can be regarded as a precursor organized in two domains with the interdomain processing site, Lys 70 -Arg 71 , being the only site accessible to the convertases in the intact precursor. Its cleavage would somehow unveil the sites present in glicentin and MPGF, which in turn would become accessible to the convertases. According to this model, an initial cleavage at the interdomain site should also occur in the intestinal pathway of processing, followed by an efficient processing of the C-terminal domain, MPGF, to yield tGLP-1, IP-2, and GLP-2. However, the set of proglucagon-derived peptides identified in the intestine does not exclude an alternative hypothesis involving an early cleavage at another site. Regarding the convertase(s) responsible for the processing of proglucagon to tGLP-1, our previous studies led to the hypothesis that PC3 would be involved in the cleavage of dibasic sites, and an additional unidentified convertase would be required for the processing at the monobasic site Arg 77 (22) . However, it was recently reported that when co-expressed with proglucagon PC3 is able to yield tGLP-1, thus suggesting that it could cleave at the monobasic site (40) .
To examine the intestinal pathway of proglucagon processing, and because there is no intestinal L cell-derived cell line available that accurately reproduces the intestinal processing of proglucagon (41), we have used AtT-20 cells as a model. AtT-20 cells were shown to process proglucagon to mature peptides that are normally found in intestinal L cells, namely glicentin, oxyntomodulin, and tGLP-1 (22) , suggesting that both cell types are endowed with very similar or identical convertases and thus probably display the same processing pathway. The processing pathway in AtT-20 cells was compared with that in INS-1 cells, a rat insulinoma-derived cell line known to express a very different set of convertases than AtT-20 cells. The activity of PC3 was directly assessed both in vivo by co-expression with proglucagon and in vitro by incubation of GLP-1 with a purified recombinant preparation of the enzyme. The results support the two-domain model of proglucagon and unequivocally confirm that PC3 may act alone in the intestinal pathway of proglucagon processing.
MATERIALS AND METHODS
Cell Culture-GH 4 C 1 cells, AtT-20 cells, and ␣TC1-6 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 50 g/ml streptomycin sulfate, and 50 units/ml penicillin. INS-1 cells were maintained in culture as described previously (42) . All cell lines were cultured at 37°C in a 5% CO 2 , 95% air mixture in a humidified incubator.
Isolation of Rat Islets and Islet Cell Preparation-Islets of Langerhans from adult male Sprague-Dawley rats (180 -200 g) were isolated following injection of collagenase (Serva) into the pancreatic duct. The islets were purified by a modification of the method described by Sutton et al. (43) . Single islet cell suspension was obtained by a short incubation of the islets with 0.05% trypsin, 0.5 mM EDTA (Life Technologies, Inc.). ␤-and non-␤-cell populations were separated by autofluorescenceactivated sorting using a FACStar-Plus (Becton Dickinson) as described previously (44) . The "non-␤-cell" population consists of 77% ␣-cells (glucagon-immunoreactive), 5% ␤-cells (insulin-immunoreactive), and 18% of other cell types including somatostatin and pancreatic polypeptide-producing cells.
2 Non-␤-cells, hereafter referred to as pancreatic ␣-cells were plated in 24-well plates (10 5 cells/well) coated with A-431 cell-derived extracellular matrix and incubated overnight in RPMI 1640 medium containing 10% fetal bovine serum before infection.
Preparation of A-431 Cell-derived Extracellular Matrix-A-431 epidermoid cells (ATCC) were grown in 24-well culture plates (7.5 ϫ 10 4 cells/well) for 3 days in RPMI 1640 medium (Life Technologies, Inc.) containing 10% fetal bovine serum. Deposited crude extracellular matrix was prepared as previously reported (45) . Briefly, A-431 cells at confluence were removed by sequential incubation with (a) 1% Triton X-100 in PBS (PBS is 138 mM NaCl, 2.7 mM KCl, 1.2 mM KH 2 PO 4 , 8.1 mM Na 2 HPO 4 ); (b) 2 M urea, 1 M NaCl; and (c) 8 M urea, in 100 mM Tris-HCl, pH 7.5. All extraction steps were performed for about 4 min on ice in the presence of 1 mM phenylmethylsulfonyl fluoride and 2 mM N-ethylmaleimide as protease inhibitors. The extracellular matrix was then digested for 30 min at room temperature with 10 g/ml DNase in PBS containing 1% bovine serum albumin that had been heat-denatured for 60 min at 60°C. Finally, the wells were extensively washed with PBS and blocked with 1% heat-denatured bovine serum albumin.
Adenovirus Infections-The preparations of purified recombinant adenoviruses expressing PC3 (Ad:PC3), or a mutated hamster preproglucagon (Ad:Glu) were reported previously (38, 46) . The toxicity of each adenovirus preparation used was assessed by performing a series of infections with increasing m.o.i. up to 1000, as described previously (46) . In addition, cells were metabolically labeled with [
35 S]methionine for 3 h and extracted in boiling loading buffer (47) , and an aliquot of the crude cellular lysate was resolved by SDS-PAGE (47) and revealed by fluorography to compare the incorporation of the radioactivity into proteins of the infected and control cells. This allowed us to use each virus preparation at m.o.i. that apparently do not disrupt normal cell metabolism for the pulse-chase experiments.
Metabolic Labeling and Immunoprecipitations-For pulse-chase experiments, infected and control cells were labeled in 0.4 ml of methionine-free medium containing 1 mM nonradioactive cysteine and 0. . A pair of arginines, which is present in the glucagon moiety and is not cleaved in the pancreas nor in the intestine, is also represented. Note that about 10 -20% of MPGF is converted in the pancreas to a 4-kDa N-terminally extended form of GLP-1, which is not found in the intestine. GLU, glucagon; IP, intervening peptide; OXT, oxyntomodulin.
for 2 h with 0.4 mCi [ 3 H]leucine (from ARC, St. Louis, MO, 80 Ci/mmol) and chased for 4 h. Extractions and immunoprecipitations were performed as described previously (22) . Glucagon-containing peptides were precipitated with monoclonal antibody Glu001 (from Novo-Nordisk) that recognizes equally well N-and/or C-terminally extended forms of glucagon. All the GLP-1-containing peptides were precipitated with rabbit antiserum 91022, whereas the peptides containing the N-terminal extension of GLP-1 (PG 72-77) were specifically precipitated with rabbit antiserum 165-3 (both kindly provided by J.J. Holst, Panum Institute, Copenhagen). Proglucagon, MPGF, and GLP-1-(1-36amide) were precipitated by both antisera, whereas tGLP-1 was only recognized by 91022. Immunoprecipitated material was recovered from the protein A-Sepharose beads by boiling in the loading buffer (47) prior to resolution in tricine-buffered SDS-PAGE (47) 
In Vitro Conversion of GLP-1 to tGLP-1-Synthetic GLP-1-(1-37) (from Peninsula Laboratories) was iodinated by the chloramine T method. Purified recombinant PC3 (48) was kindly provided by Dr. I. Lindberg (Louisiana State University, New Orleans). About 100,000 cpm of 125 I-labeled GLP-1 were incubated with 0.9 g PC3 in 0.1 M sodium acetate buffer, pH 5.5, containing 0.1% Triton X-100, 50 M dithiothreitol, and 10 mM CaCl 2 . In control reactions CaCl 2 was replaced with 1 mM EDTA. Reactions were incubated at 37°C for up to 16 h and stopped by boiling, and 10 l was analyzed by SDS-PAGE (47) . Based on activity on Cbz-Arg-Ser-Lys-Arg-AMC (49), the purified preparation of PC3 used in this work was four times more active than the crude preparation used earlier (22) .
RESULTS

Kinetics of Cleavage in the Processing of Proglucagon in
AtT-20 and INS-1 Cells-Proglucagon processing was examined in AtT-20 cells as a model of intestinal L cells to investigate the kinetics of the cleavages during the processing of proglucagon to tGLP-1. To study the processing of proglucagon in an appropriate cellular environment, proglucagon was expressed with a recombinant adenovirus vector in endocrine cell lines. The use of a replication-deficient viral vector allowed high levels of expression to be reached that are generally observed for neuroendocrine precursors without the problems arising from the replication of the virus in the cell such as the inhibition of host cell protein synthesis that may disturb the complex mechanisms of intracellular transport and sorting intimately associated with the processing. Fig. 2 shows the result of a pulse-chase experiment carried out in AtT-20 cells. Proglucagon disappeared with the concomitant appearance of glicentin and MPGF, two intermediates identified previously in ␣TC1-6 cells (8). These two peptides were first detected after 10 min of chase. Therefore, the first cleavage in proglucagon processing occurs at the Lys 70 -Arg 71 site of the precursor as in ␣TC1-6 cells. However, the fate of both of these intermediates was very different in AtT-20 cells from what was observed in ␣TC1-6 cells. Glicentin was partially and slowly converted to oxyntomodulin and presumably GRPP ( Fig. 2A) . Low levels of glucagon could be detected only after the longest times of chase (2 and 4 h) and following overexposure of the gels, consistent with the prior detection of this peptide in proglucagon-expressing AtT-20 cells (22, 50) . Thus the rates of cleavage were very different for the Lys 31 -Arg 32 site at the N terminus of glucagon (50 to 75% cleavage in 4 h) and for the Lys 62 -Arg 63 site at its C terminus (less than 5% cleavage). On the other hand, amounts of MPGF transiently increased and then rapidly decreased with a peak at 20 and 30 min of chase (Fig. 2B) . At the same time two new GLP-1-containing peptides started to accumulate with apparent molecular masses of 7 and 3.4 kDa (Fig. 2B) . Unlike proglucagon and MPGF, these two peptides were not immunoprecipitated by antiserum 165-3, which is specific for the N terminus of GLP-1-(1-37) (data not shown). This suggested that they both lack this extension as a consequence of the cleavage at the monobasic site Arg 77 . The 3.4 kDa peptide immunoprecipitated by antiserum 91022 was previously identified as tGLP-1 by radiosequencing (22) . Similarly, based on its lack of N-terminal extension and its electrophoretic migration (slightly faster than that of MPGF), the 7-kDa peptide is identified as a truncated form of MPGF cleaved at Arg 77 (tMPGF). tMPGF and tGLP-1 accumulated with different kinetics. tMPGF levels raised and then slowly decreased after 30 min of chase, which is consistent with it being an intermediate, whereas tGLP-1 accumulated at a lower rate with no later decrease, as would be expected for the final product of the processing pathway (Fig.  2B) . Lower levels of the 4-kDa GLP-1 (a peptide previously identified as GLP-1- (1-36amide) and/or GLP-1-(1-37) (8) also detected after overexposure at 20 and 30 min of chase. As summarized in Fig. 2C , these results indicated that during the conversion of MPGF to tGLP-1, the monobasic site Arg 77 was cleaved faster and more efficiently than the dibasic site Arg 109 -Arg 110 at the C terminus of GLP-1. Therefore, the major substrate for the monobasic convertase appears to be MPGF in vivo although the 4-kDa GLP-1 is also cleaved. Fig. 3 shows the result of a similar pulse-chase experiment in INS-1 cells, a rat insulinoma-derived cell line that expresses high levels of PC2 and reduced levels of PC3 (33, 51) . As in AtT-20 cells, proglucagon was initially cleaved to glicentin and MPGF in INS-1 cells. However, the fate of both domains was very different in the two cell lines examined. In INS-1 cells (Fig. 3A) , glicentin was completely processed to glucagon in 4 h with the transient appearance of the two intermediates already identified in ␣TC1-6 cells, namely oxyntomodulin and proglucagon-(1-61) (8) . This pattern is similar to that observed in ␣TC1-6 cells. It indicates that both sites Lys 31 -Arg 32 and Lys 62 -Arg 63 at the N-and C termini of glucagon were cleaved with very close rates. In contrast, MPGF accumulated intact for the major part and was only partially cleaved to tMPGF and tGLP-1 with no detectable 4 kDa GLP-1 (Fig. 3B) in contrast to what was observed in ␣TC1-6 cells. Although the cleavages were partial, the pattern again suggests a higher rate of cleavage for the monobasic site than for the dibasic site at both ends of tGLP-1 (Fig. 3C) .
Co-expression of Proglucagon and PC3 in GH 4 C 1 and ␣-Cells-To study the cleavage specificity of PC3 in vivo, proglucagon and PC3 were co-expressed in GH 4 C 1 cells, a rat pituitary-derived cell line that expresses no detectable levels of PC2 and PC3. When proglucagon was expressed alone, the major proglucagon-derived peptide present in cell lysates after 3 h of chase was proglucagon itself (Fig. 4) . Low levels of glicentin and MPGF were readily detected, and lower levels of 7-kDa tMPGF and 3.4-kDa tGLP-1 were also seen after overexposure. This is consistent with previous reports that GH 4 C 1 cells process proglucagon very poorly (22, 52) . By contrast, when PC3 was co-expressed, proglucagon and MPGF levels were strongly reduced with the concomitant dramatic increase in oxyntomodulin (a peptide not detected without PC3), tGLP-1 and tMPGF levels. Glicentin was enhanced to a lesser extent. However, even after overexposure, neither glucagon nor 4-kDa GLP-1 were detected. This pattern of processing is similar to that observed in AtT-20 cells and strongly suggests that PC3 alone is able to reconstitute the intestinal pathway of proglucagon processing including the monobasic cleavage at Arg 77 . Alternatively, PC3 might also reveal the presence in GH 4 C 1 cells of a latent endogenous monobasic activity due to another enzyme that could only act after PC3 has cleaved proglucagon at the interdomain site to generate a more suitable substrate such as MPGF.
␣TC1-6 cells and pancreatic ␣-cells are known to be devoid of endogenous monobasic activity, because MPGF accumulates as a major end product and is only partially cleaved into 4-kDa GLP-1 but not to tMPGF or tGLP-1 (8) . We therefore expressed PC3 in ␣TC1-6 cells and primary rat pancreatic ␣-cells in culture to directly assess the monobasic activity of this convertase in vivo on the endogenously expressed proglucagon (Fig.  5) . Both cell types were found to be resistant to the infection by adenovirus at low m.o.i.; probably because of a lack of a specific receptor at their surface. However, increasing the amounts of virus applied to the cells allowed for the expression of the transgene, presumably by increasing the uptake of the virus through nonspecific mechanisms (data not shown). In ␣TC1-6 cells infected with Ad:PC3, MPGF and 4-kDa GLP-1 levels were reduced, whereas both tMPGF and tGLP-1 levels rose lanes 3 and 6) . The day after, cells were labeled for 30 min with [ 35 S]methionine and chased for 3 h. Cells were lysed and lysates were immunoprecipitated with anti-glucagon antibody Glu001 (lanes 1-3) or anti-GLP-1 antiserum 91022 (lanes 4 -6) . Immunoprecipitated material was analyzed by SDS-PAGE and fluorography. Abbreviations are as described in Fig. 2 . The additional bands that appear at about 10 kDa (lanes 4 -6) and above proglucagon (all lanes) are likely to be nonspecific, because they are present in mock-transfected cells. (Fig. 5A) . Similarly, in primary ␣-cells, PC3 converted MPGF into tGLP-1 (Fig. 5B) . These results thus confirm that PC3 is able to cleave the monobasic site of proglucagon in vivo.
In Vitro Conversion of GLP-1 to tGLP-1 by Recombinant Purified PC3-The data above show that PC3 is important for tGLP-1 production in vivo. This finding is consistent with an earlier report indicating that PC3 is indeed able to cleave proglucagon at both Lys 70 -Arg 71 and Arg 109 -Arg 110 sites in vitro, two cleavages involved in the processing of proglucagon to tGLP-1 (23), but not with our preceding report that PC3 did not cleave the monobasic site of GLP-1 (22) . To reinvestigate whether PC3 could cleave the monobasic site, iodinated GLP-1-(1-37) was incubated with purified recombinant PC3. Although the purified preparation of the enzyme used in this experiment was four times more active than the crude preparation used previously based on its activity on the fluorigenic substrate Cbz-Arg-Ser-Lys-Arg-AMC (49) , no cleavage could be detected up to 4 h of incubation at 37°C (data not shown). However, a calcium-dependent partial conversion to 3.4-kDa tGLP-1 was observed after 16 h (Fig. 6) . No smaller products were detected, demonstrating the specificity of the cleavage and the absence of contaminating proteolytic activity. This result provides the first demonstration that PC3 is able to cleave the monobasic site of proglucagon in vitro. Interestingly, for the three cell lines examined, endogenous convertases can cleave efficiently at internal sites in glicentin and/or MPGF after the initial cleavage at the interdomain site, but apparently do not cleave these sites in the intact precursor at a detectable level. These data support the hypothesis that Lys 70 -Arg 71 is the most accessible site in the intact precursor. Even in GH 4 C 1 cells, which express no detectable levels of PC2 and PC3, the pattern of processing is consistent with an initial cleavage at Lys 70 -Arg 71 followed by a partial conversion of MPGF to tMPGF and tGLP-1. Whether this partial processing results from the action of low undetected levels of PC3 or of another endogenous convertase such as PC6 and furin (3) remains to be determined. Nevertheless these data again suggest that the early cleavage at the interdomain site reflects more of a structural property of the precursor rather than the specificity of a particular convertase. An initial cleavage at this site may trigger conformational changes at other sites that in turn become better substrates for the convertases as previously suggested in the case of proinsulin (54) . These results fit the two-domain model previously proposed for proglucagon (1) and do not support the alternative hypothesis of a differential processing initiated by cleavages at two distinct sites in the precursor as suggested in the case of prothyrotropin-releasing hormone (55) .
After this initial cleavage, which apparently is equally well carried out by PC2 and by PC3, the kinetics of the subsequent steps are probably driven by different specificities of the convertases for the various sites present in glicentin and MPGF. The cleavages performed by these convertases are summarized in Fig. 7 (1-36amide) ; other abbreviations are as described in Fig. 2.   FIG. 6. PC3-mediated in vitro conversion of GLP-1 to tGLP-1 . 125 I-labeled GLP-1-(1-37) was incubated at 37°C for 16 h with purified recombinant PC3 in sodium acetate buffer, pH 5.5, in the presence of 10 mM CaCl 2 or EDTA as indicated above the lanes. Reactions were stopped by boiling, and an aliquot was analyzed by SDS-PAGE and autoradiography. The migration of the 4-and 3.4-kDa markers is indicated.
the production of glucagon in INS-1 cells because these cells express high levels of PC2 (51) . The low amounts of glucagon detected in AtT-20 cells may also be an indication of the presence of low levels of PC2 in these cells as reported by others (3) even though it could not be detected by Western blot (6, 22, 53) . Alternatively, another unidentified convertase or the very high levels of PC3 that are present in AtT-20 cells might be responsible for the limited conversion of oxyntomodulin to glucagon. Such an enhancement of a cleavage at a less favored site in ␤-lipotropin has been reported in AtT-20 cells overexpressing PC3 (56) , suggesting that the specificity of cleavage may be dependent on the level of expression of the convertase. However, in the case of oxyntomodulin, this possibility is not supported by the results of the experiment of co-expression in GH 4 C 1 cells. Using higher levels of PC3 did not allow the detection of glucagon in cell lysates (data not shown).
Our previous hypothesis that PC3 would be involved in the cleavage of dibasic sites and that an additional unidentified convertase would be required for the processing at the monobasic site Arg 77 turned out to be incorrect. The observations presented here, as well as the results from Dhanvantari et al. (40) reported while this work was in progress, clearly show that PC3 is able to cleave the monobasic site in vivo in addition to dibasic sites. Surprisingly, this monobasic site, which lacks both a P2 basic and a P4 Arg residues, is cleaved significantly faster than the dibasic site Arg 109 -Arg 110 at the C terminus of GLP-1 even though the latter site has Arg residues both in P2 and P4 positions, a structural feature shown to favor the cleavage of other substrates (57) (58) (59) . As a consequence of this unusual site preference, the major intermediate in the conversion of MPGF to tGLP-1 is tMPGF, a truncated form of MPGF. On the other hand, unlike proinsulin conversion, which could be readily studied in vitro even with partially purified convertases (60), the monobasic cleavage of proglucagon turned out to be difficult to reproduce in an in vitro assay (22) . Such a discrepancy between in vivo and in vitro activity of a convertase has been encountered previously for the PC2-mediated cleavage of proglucagon at the site Lys 62 -Arg 63 (23) . One possibility could have been that GLP-1, the peptide used as a substrate for the in vitro assay, is not a good substrate for PC3, because the pulse-chase experiments revealed that the major substrate actually is MPGF in vivo. However, preliminary experiments with purified metabolically labeled MPGF as a substrate also resulted in only very limited cleavage (data not shown). It has been reported that PC3 undergoes C-terminal truncation in the trans-Golgi network or the immature secretory granule (61) and that this truncation greatly enhances the activity of the convertase toward a number of substrates (62) (63) (64) . Accordingly, the monobasic site of proglucagon could be a better substrate for a truncated form of PC3. The fact that the monobasic activity of recombinant full-length PC3 was observed in vitro only after longer incubations certainly tends to support this hypothesis, because this truncation was reported to be autocatalytic (62) .
In conclusion, the results support the concept that both the conformation of the precursor and the specificity of the convertases are of importance for determining the temporal order of the cleavages during the maturation of proglucagon. In addition, they unequivocally confirm that PC3 is able to perform all the cleavages necessary for the production of tGLP-1 and thus may act alone in the intestinal pathway of proglucagon processing. Whether this actually occurs in the intestinal L cells must await studies with primary L cells in culture or with mice disrupted for the gene of the convertase. Finally, given the physiological actions of tGLP-1 both as an incretin (26, 65, 66) and as a neuromediator of satiety (67) , in addition to the reported impaired proinsulin and pro-opiomelanocortin processing, our results may be relevant to the reported obesity and abnormal glucose homeostasis of a patient having mutations impairing PC3 activity (68) .
